BioSpace News Archive

For years, PTC Therapeutics has attempted to win regulatory approval for its DMD drug, Translarna. Now, the company believes it has data that will support another filing for FDA approval.

The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.

Acer Therapeutics and Relief Therapeutics announced the FDA has denied their NDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.

Researchers at Imperial College London have developed a novel diagnosis method with a high rate of correct Alzheimer’s diagnosis and the ability to determine the patient’s progression stage.

ADMA Biologics, Inc. announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

Inivata, a leader in liquid biopsy, announces new data in support of its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of its third-party pilot production.

Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg 2+ is the Core Patented Technology of TNX-1900 for Migraine.

EyePoint Pharmaceuticals, Inc. today announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that on June 22, 2022 at 11am EST, Dr. Allen Davidoff, XORTX’s CEO, will host a “Fireside Chat” that will include a presentation “Exciting Developments in New Therapies for Progressive Kidney Diseases”.